Corbus Pharmaceuticals Holdings, Inc. (CRBP): Nasdaq/NYSE listing notice — Corbus receives FDA IND clearance for CRB-601; Nasdaq grants extension to May 8, 2024

Corbus Pharmaceuticals Holdings, Inc.

FDA cleared IND for CRB-601, a TGFβ blocking monoclonal antibody targeting integrin αvβ8.
Phase 1 study first participant enrollment expected in H1 2024; pre-clinical data showed enhanced anti-tumor activity.
Nasdaq granted extension until May 8, 2024 to regain compliance with $2.5M stockholders' equity requirement, conditional on capital raise.
Stockholders' equity was $311,016 as of Sep 30, 2023, below the $2.5M minimum; alternative standards not met.
Failure to regain compliance by May 8, 2024 may lead to delisting; company has right to appeal.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Corbus Pharmaceuticals Holdings, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: extension granted
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5550(b)(1), because the Company’s stockholders’ equity of $311,016, as reported in the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2023, was below the required minimum of $2.5 million, and because, as of November 9,

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-003197

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.